Literature DB >> 3023432

Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations.

V Pistoia, A J Carroll, E F Prasthofer, A B Tilden, K S Zuckerman, M Ferrarini, C E Grossi.   

Abstract

Cell lines were established from purified large granular lymphocytes (LGL) isolated from the peripheral blood of seven patients with phenotypically homogeneous LGL expansions. LGL were stimulated with phytohemagglutinin (PHA) or recombinant interleukin-2 (rIL-2) and further expanded in vitro in IL-2-containing media. The surface phenotype of LGL, as assessed by monoclonal antibody staining, was T3+ T8+ in five patients, T3- T8- in one, and T3+ T8- in another patient. The cells also expressed Leu 7, Leu 11, and/or OKM 1 markers in various proportions and were identifiable as LGL by their morphological and cytochemical features. The original surface phenotype of the unstimulated LGL was retained in the IL-2-dependent cell lines from each individual patient, i.e., T3+ T8+ cells originated T3+ T8+ cell lines and T3- T8- cells originated T3- T8- cell lines. Other markers, such as Leu 11 and OKM 1, were generally lost in culture. LGL proliferated in response to rIL-2 but did not express detectable IL-2 receptors, even after prolonged periods of culture. All cell lines from each individual patient had the same surface phenotype, and within the single lines, all of the cells expressed the same markers. Cell lines from two patients consistently displayed chromosomal abnormalities. Although different in the two patients, the abnormalities were identical in all of the lines from the same patient and detectable in most of the cells examined, suggesting a clonal origin for the abnormally expanded LGL populations. Freshly isolated LGL did not exert NK activity. However, the IL-2-dependent LGL lines acquired the ability to kill K562 target cells and to produce gamma interferon (gamma-IFN). No direct correlation was observed between these two properties.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023432     DOI: 10.1007/bf00915251

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  40 in total

Review 1.  Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia.

Authors:  S M Fu; N Chiorazzi; H G Kunkel
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 2.  Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets.

Authors:  E Saksela; T Timonen; A Ranki; P Häyry
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

4.  Large granular lymphocytes in human peripheral blood: ultrastructural and cytochemical characterization of the granules.

Authors:  C E Grossi; A Cadoni; A Zicca; A Leprini; M Ferrarini
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

5.  Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders.

Authors:  A C Aisenberg; T G Krontiris; T W Mak; B M Wilkes
Journal:  N Engl J Med       Date:  1985-08-29       Impact factor: 91.245

6.  In vitro expansion and analysis of cloned cytotoxic T cells derived from patients with chronic T gamma lymphoproliferative disorders.

Authors:  R J van de Griend; R L Bolhuis
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

7.  Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties.

Authors:  D C Linch; J M Lipton; D G Nathan
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  Chronic T cell lymphocytosis: a review of 21 cases.

Authors:  A C Newland; D Catovsky; D Linch; J C Cawley; P Beverley; J F San Miguel; E C Gordon-Smith; T E Blecher; S Shahriari; S Varadi
Journal:  Br J Haematol       Date:  1984-11       Impact factor: 6.998

9.  T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells.

Authors:  A Rambaldi; P G Pelicci; P Allavena; D M Knowles; S Rossini; R Bassan; T Barbui; R Dalla-Favera; A Mantovani
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity.

Authors:  G Degliantoni; B Perussia; L Mangoni; G Trinchieri
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  4 in total

1.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

Authors:  M Tsudo; C K Goldman; K F Bongiovanni; W C Chan; E F Winton; M Yagita; E A Grimm; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.

Authors:  R Zambello; T Chisesi; C Agostini; L Trentin; M Masciarelli; G Gasparotto; M Vespignani; G Casorati; R Foa; G Semenzato
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

Review 4.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.